Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Advanced cSCC in Solid Organ Transplant Recipients
NCT04807777Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in cutaneous squamous cell carcinoma (cSCC), sponsored by Columbia University. Started Apr 2022; status: terminated.
02
Drugs
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04807777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04807777.